 Jennifer Black
Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 8 | 2024 | 207 | 1.840 |
Why?
| | Soft Tissue Neoplasms | 5 | 2024 | 131 | 1.520 |
Why?
| | Bone Neoplasms | 2 | 2024 | 265 | 0.740 |
Why?
| | Pathology, Surgical | 1 | 2016 | 6 | 0.490 |
Why?
| | Xeroderma Pigmentosum | 1 | 2016 | 9 | 0.470 |
Why?
| | Medical Records | 1 | 2016 | 192 | 0.460 |
Why?
| | Neurilemmoma | 2 | 2017 | 25 | 0.440 |
Why?
| | Eosinophilic Esophagitis | 2 | 2024 | 332 | 0.280 |
Why?
| | Neoadjuvant Therapy | 3 | 2021 | 467 | 0.280 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2019 | 212 | 0.260 |
Why?
| | Lymph Nodes | 1 | 2010 | 509 | 0.260 |
Why?
| | Tocolytic Agents | 1 | 2006 | 16 | 0.240 |
Why?
| | Indomethacin | 1 | 2006 | 76 | 0.240 |
Why?
| | Ductus Arteriosus | 1 | 2006 | 72 | 0.230 |
Why?
| | Twins, Monozygotic | 1 | 2006 | 133 | 0.230 |
Why?
| | Head and Neck Neoplasms | 1 | 2010 | 561 | 0.220 |
Why?
| | Gastritis, Hypertrophic | 1 | 2004 | 4 | 0.210 |
Why?
| | Molecular Medicine | 1 | 2024 | 1 | 0.210 |
Why?
| | Keratins | 1 | 2024 | 171 | 0.200 |
Why?
| | Edema | 1 | 2004 | 125 | 0.200 |
Why?
| | Infarction | 1 | 2003 | 9 | 0.200 |
Why?
| | Choriocarcinoma | 1 | 2003 | 9 | 0.200 |
Why?
| | Public Opinion | 1 | 2024 | 62 | 0.200 |
Why?
| | Child | 16 | 2024 | 22740 | 0.200 |
Why?
| | Diarrhea | 1 | 2004 | 193 | 0.190 |
Why?
| | Biomarkers, Tumor | 4 | 2018 | 1329 | 0.190 |
Why?
| | Kidney Neoplasms | 2 | 2018 | 415 | 0.190 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 20 | 0.190 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2003 | 63 | 0.190 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 44 | 0.180 |
Why?
| | Cytomegalovirus Infections | 1 | 2004 | 206 | 0.180 |
Why?
| | Uterine Neoplasms | 1 | 2003 | 98 | 0.180 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2023 | 107 | 0.180 |
Why?
| | Receptor, trkA | 2 | 2019 | 18 | 0.180 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 68 | 0.180 |
Why?
| | Homeodomain Proteins | 2 | 2017 | 523 | 0.180 |
Why?
| | Immunohistochemistry | 4 | 2018 | 1723 | 0.160 |
Why?
| | Pyrimidines | 2 | 2023 | 530 | 0.160 |
Why?
| | Sulfonamides | 2 | 2023 | 583 | 0.160 |
Why?
| | Virtual Reality | 1 | 2021 | 82 | 0.150 |
Why?
| | Humans | 31 | 2024 | 145783 | 0.150 |
Why?
| | Neoplasms, Connective and Soft Tissue | 1 | 2019 | 1 | 0.150 |
Why?
| | Death, Sudden | 1 | 2019 | 26 | 0.140 |
Why?
| | Child, Preschool | 12 | 2021 | 11868 | 0.140 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 239 | 0.140 |
Why?
| | Nephroma, Mesoblastic | 1 | 2018 | 2 | 0.140 |
Why?
| | Fibrosarcoma | 1 | 2018 | 23 | 0.140 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2018 | 18 | 0.140 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2017 | 15 | 0.130 |
Why?
| | Drug Therapy | 1 | 2018 | 84 | 0.130 |
Why?
| | Ifosfamide | 3 | 2023 | 39 | 0.130 |
Why?
| | Gene Rearrangement | 1 | 2018 | 156 | 0.130 |
Why?
| | Abdominal Neoplasms | 1 | 2017 | 47 | 0.130 |
Why?
| | Peripheral Nervous System Neoplasms | 1 | 2017 | 19 | 0.130 |
Why?
| | Neuroblastoma | 2 | 2017 | 174 | 0.130 |
Why?
| | Sarcoma, Synovial | 1 | 2017 | 20 | 0.130 |
Why?
| | Airway Obstruction | 1 | 2019 | 153 | 0.130 |
Why?
| | Bronchi | 1 | 2019 | 263 | 0.130 |
Why?
| | Radiotherapy | 1 | 2018 | 206 | 0.130 |
Why?
| | Hemangiosarcoma | 1 | 2017 | 25 | 0.130 |
Why?
| | Cytodiagnosis | 1 | 2017 | 31 | 0.120 |
Why?
| | Frozen Sections | 1 | 2017 | 24 | 0.120 |
Why?
| | Neurofibromatosis 1 | 1 | 2017 | 57 | 0.120 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 271 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1150 | 0.120 |
Why?
| | Macrophages | 1 | 2024 | 1507 | 0.120 |
Why?
| | Placenta | 1 | 2003 | 787 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1969 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 827 | 0.110 |
Why?
| | Bone Marrow Neoplasms | 1 | 2015 | 3 | 0.110 |
Why?
| | Transcription Factors | 2 | 2015 | 1736 | 0.110 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2015 | 17 | 0.110 |
Why?
| | Doxorubicin | 3 | 2023 | 403 | 0.110 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 52 | 0.110 |
Why?
| | Anemia, Sickle Cell | 1 | 2019 | 318 | 0.110 |
Why?
| | Thyroid Gland | 1 | 2015 | 91 | 0.100 |
Why?
| | Adolescent | 13 | 2021 | 22577 | 0.100 |
Why?
| | Biopsy | 1 | 2017 | 1082 | 0.100 |
Why?
| | Enterochromaffin-like Cells | 1 | 2012 | 2 | 0.100 |
Why?
| | Gastritis, Atrophic | 1 | 2012 | 5 | 0.100 |
Why?
| | Infant, Newborn | 5 | 2023 | 6465 | 0.090 |
Why?
| | Gastric Mucosa | 1 | 2012 | 54 | 0.090 |
Why?
| | Estrogen Receptor beta | 1 | 2012 | 40 | 0.090 |
Why?
| | Osteoblastoma | 1 | 2012 | 2 | 0.090 |
Why?
| | Eosinophilia | 1 | 2015 | 224 | 0.090 |
Why?
| | Female | 18 | 2021 | 79045 | 0.090 |
Why?
| | Fatal Outcome | 2 | 2019 | 305 | 0.090 |
Why?
| | Adult | 12 | 2023 | 40881 | 0.090 |
Why?
| | Fibroma | 1 | 2012 | 21 | 0.090 |
Why?
| | Argininosuccinate Lyase | 1 | 2011 | 1 | 0.090 |
Why?
| | Argininosuccinic Aciduria | 1 | 2011 | 2 | 0.090 |
Why?
| | Cyclooxygenase 2 | 1 | 2012 | 167 | 0.090 |
Why?
| | Indazoles | 2 | 2023 | 85 | 0.090 |
Why?
| | Receptors, Androgen | 1 | 2012 | 149 | 0.090 |
Why?
| | Osteosarcoma | 1 | 2012 | 89 | 0.090 |
Why?
| | Young Adult | 8 | 2021 | 14254 | 0.080 |
Why?
| | Infant | 7 | 2019 | 10091 | 0.080 |
Why?
| | Male | 16 | 2023 | 73011 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 474 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2012 | 322 | 0.080 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2012 | 431 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 2219 | 0.070 |
Why?
| | Signal Transduction | 2 | 2012 | 5224 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 3 | 2018 | 2399 | 0.070 |
Why?
| | Nitric Oxide | 1 | 2011 | 892 | 0.060 |
Why?
| | Polyhydramnios | 1 | 2006 | 17 | 0.060 |
Why?
| | Fetofetal Transfusion | 1 | 2006 | 26 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1271 | 0.060 |
Why?
| | Congenital Abnormalities | 1 | 2006 | 109 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 971 | 0.050 |
Why?
| | Hypoalbuminemia | 1 | 2004 | 27 | 0.050 |
Why?
| | Tissue Array Analysis | 2 | 2015 | 49 | 0.050 |
Why?
| | Pregnancy Trimester, Third | 1 | 2003 | 119 | 0.050 |
Why?
| | Adenoviridae | 1 | 2023 | 199 | 0.040 |
Why?
| | Fibrosis | 1 | 2024 | 561 | 0.040 |
Why?
| | Premature Birth | 1 | 2006 | 390 | 0.040 |
Why?
| | Pregnancy | 2 | 2006 | 7216 | 0.040 |
Why?
| | Diagnosis, Differential | 2 | 2017 | 1512 | 0.040 |
Why?
| | Dyspnea | 1 | 2023 | 250 | 0.040 |
Why?
| | Prospective Studies | 3 | 2019 | 8078 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2017 | 2000 | 0.040 |
Why?
| | Margins of Excision | 1 | 2021 | 50 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 282 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2021 | 288 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2023 | 1043 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2020 | 222 | 0.040 |
Why?
| | Tumor Burden | 1 | 2021 | 325 | 0.040 |
Why?
| | Esophagoscopy | 1 | 2021 | 223 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2024 | 2191 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 427 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4568 | 0.040 |
Why?
| | Receptor, trkC | 1 | 2018 | 10 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2018 | 14 | 0.030 |
Why?
| | Hypoxia | 1 | 2006 | 1199 | 0.030 |
Why?
| | Fibroblast Growth Factor 1 | 1 | 2018 | 13 | 0.030 |
Why?
| | Receptor, trkB | 1 | 2018 | 39 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 72 | 0.030 |
Why?
| | Gene Dosage | 1 | 2018 | 145 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1188 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 2018 | 166 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 188 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2017 | 69 | 0.030 |
Why?
| | Aged | 3 | 2015 | 26217 | 0.030 |
Why?
| | Hepatoblastoma | 1 | 2017 | 52 | 0.030 |
Why?
| | Age Factors | 1 | 2004 | 3346 | 0.030 |
Why?
| | Age of Onset | 1 | 2018 | 557 | 0.030 |
Why?
| | Teratoma | 1 | 2017 | 124 | 0.030 |
Why?
| | Extremities | 1 | 2017 | 142 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2017 | 165 | 0.030 |
Why?
| | Middle Aged | 5 | 2020 | 36309 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 499 | 0.030 |
Why?
| | Synaptophysin | 1 | 2015 | 15 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2015 | 18 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 534 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2094 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 688 | 0.030 |
Why?
| | Rhabdomyosarcoma | 1 | 2015 | 65 | 0.030 |
Why?
| | Wilms Tumor | 1 | 2015 | 90 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 10919 | 0.030 |
Why?
| | Sarcoma, Ewing | 1 | 2015 | 103 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2015 | 336 | 0.020 |
Why?
| | Diet | 1 | 2021 | 1278 | 0.020 |
Why?
| | Biomarkers | 1 | 2024 | 4302 | 0.020 |
Why?
| | Smad2 Protein | 1 | 2012 | 37 | 0.020 |
Why?
| | Metaplasia | 1 | 2012 | 57 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2123 | 0.020 |
Why?
| | Hyperplasia | 1 | 2012 | 177 | 0.020 |
Why?
| | Argininosuccinate Synthase | 1 | 2011 | 1 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2012 | 143 | 0.020 |
Why?
| | Mice | 2 | 2024 | 18356 | 0.020 |
Why?
| | Nitrites | 1 | 2011 | 88 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 1042 | 0.020 |
Why?
| | Nitric Oxide Synthase | 1 | 2011 | 234 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4330 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2011 | 334 | 0.020 |
Why?
| | Thyroid Neoplasms | 1 | 2015 | 370 | 0.020 |
Why?
| | beta Catenin | 1 | 2012 | 254 | 0.020 |
Why?
| | Arginine | 1 | 2011 | 264 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2018 | 2050 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5428 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3170 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 638 | 0.020 |
Why?
| | Swine | 1 | 2011 | 826 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 778 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2865 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3418 | 0.020 |
Why?
| | Animals | 2 | 2024 | 38102 | 0.020 |
Why?
| | Cell Line | 1 | 2011 | 2823 | 0.010 |
Why?
| | Fibroblasts | 1 | 2011 | 1028 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2011 | 878 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3130 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 8347 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 5993 | 0.010 |
Why?
| | United States | 1 | 2018 | 16126 | 0.010 |
Why?
|
|
Black's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|